Results 81 to 90 of about 10,168 (211)

A role for iNKT cells in sarcopenia

open access: yes, 2020
Objective: Sarcopenia or the detrimental muscle ageing, represent an important unmet clinical health problem. Most pathophysiological studies suggest an effect of the immune system, primarily through catabolic cytokine productions such as IL-6.
Decruy, Tine   +6 more
core  

White Adipose Tissue Browning and Cross Talk With Metabolic Diseases and Tumors: From Molecular Mechanisms to Clinical Translation

open access: yesMed Research, Volume 2, Issue 2, Page 280-308, June 2026.
White adipose tissue undergoes browning under endogenous and exogenous stimuli, primarily regulated by core molecules such as PRDM16 and UCP1. It exhibits a double‐edged sword effect in metabolic diseases and tumors: while mitigating metabolic disease impacts and suppressing early‐stage tumors through nutritional competition, it may accelerate cachexia
Yingjiao Wang   +12 more
wiley   +1 more source

A party of three: iNKT cells in GVHD prevention [PDF]

open access: yesBlood, 2015
In this issue of Blood, Schneidawind et al demonstrate that the adoptive transfer of CD4+ invariant natural killer T (iNKT) cells from third-party mice protects from lethal graft-versus-host disease (GVHD) through expansion of donor regulatory T cells (Tregs) in a murine model of allogeneic hematopoietic cell transplantation (HCT).
Annkristin, Heine, Peter, Brossart
openaire   +2 more sources

iNKT cells were activated during acute phase of dengue infection.

open access: yes, 2014
a) Representative dot plot and histogram demonstrate gating strategy for iNKT cells and CD69 expression on iNKT cells. iNKT cells were gated, within lymphocytes population, on CD3+, PBS57-loaded CD1d tetramer+ (in comparison with unloaded CD1d tetramer ...
Prida Malasit (36883)   +10 more
core   +1 more source

The RNA‐ and DNA‐Binding Protein Y‐Box Binding Protein 1 (YB‐1) Regulates iNKT Cell Development

open access: yesEuropean Journal of Immunology, Volume 56, Issue 5, May 2026.
YB‐1 is essential for invariant NKT cell development, integrating TCR, co‐stimulatory, and IL‐15 signaling to control maturation, subset differentiation, and survival. Its loss at the double‐positive thymocyte stage causes ∼80% iNKT cell depletion, maturation arrest, impaired cytokine production, and increased apoptosis.
Silvia Schulze   +7 more
wiley   +1 more source

The My(c)stery of iNKT cell ontogeny [PDF]

open access: yesCell Cycle, 2009
Invariant V alpha 14 bearing natural killer T cells (iNKT) cells constitute a subset of lymphocytes that recognize lipid-based ligands presented by the non-classical MHC class I-like molecule CD1d and responds with rapid cytokine production. Despite their multiple implications in regulating immune responses, pertaining to cancer and auto-immunity, the ...
Marei, Dose, Fotini, Gounari
openaire   +2 more sources

Immune therapy in multiple myeloma : can iNKT cells be targeted? [PDF]

open access: yes, 2017
Multiple myeloma (MM) is a plasma cell cancer where, despite the major therapeutic advances, still the majority of patients relapse and develop a non-responsive disease. Consequently, there’s an urgent need for the development of new treatments.
Favreau, Mérédis
core  

Murine iNKT cells are depleted by liver damage via activation of P2RX7 [PDF]

open access: yes, 2020
Invariant natural killer T cells (iNKT) constitute up to 50% of liver lymphocytes and contribute to immunosurveillance as well as pathogenesis of the liver. Systemic activation of iNKT cells induces acute immune-mediated liver injury. However, how tissue
Regina Stark   +22 more
core   +1 more source

NF-κB is activated in CD4+ iNKT cells by sickle cell disease and mediates rapid induction of adenosine A2A receptors.

open access: yesPLoS ONE, 2013
Reperfusion injury following tissue ischemia occurs as a consequence of vaso-occlusion that is initiated by activation of invariant natural killer T (iNKT) cells.
Gene Lin   +6 more
doaj   +1 more source

Nanotechnology Meets Immunotherapy: Crosstalks Against Cancer

open access: yesImmunity, Inflammation and Disease, Volume 14, Issue 5, May 2026.
ABSTRACT Background The convergence of nanotechnology and immunotherapy has ushered in a transformative era in cancer treatment, offering new strategies to overcome pharmacokinetic limitations and immune evasion associated with conventional therapies. While immunotherapy, spanning checkpoint inhibitors, adoptive cell transfer, and cancer vaccines, has ...
Nima Javanmehr   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy